Xi’an Deli Biochemical Industry Co., Ltd. has officially announced the expansion of its active pharmaceutical ingredient (API) and excipient portfolio with the addition of Glucosamine Sulfate Sodium Chloride (CAS 1296149-13-7). Backed by over 26 years of specialized manufacturing experience, the company aims to provide high-purity ingredients, full technical documentation, and scalable global supply support for joint health formulations and pharmaceutical development. Building on its established leadership in cyclodextrin derivatives—such as Hydroxypropyl Betadex (HPBCD) and Sulfobutyl Ether Beta Cyclodextrin Sodium (SBECD)—Xi’an Deli’s latest release reinforces its strategy to deliver diversified, high-quality solutions for pharmaceutical manufacturers and partners across Europe, Asia, and global markets.
Cyclodextrins gained significant attention in pharmaceutical research after scientists such as Loftsson, Stella, and other researchers explored their unique molecular structure and solubilizing properties from 2005 to 2018. Studies conducted in universities and pharmaceutical research institutions worldwide demonstrated that cyclodextrins improve drug solubility, stability, and bioavailability, leading to their increasing application in modern drug delivery systems.
Recently, Xi'an DELI Biochemical announced new progress in the application of Betadex Sulfobutyl Ether Sodium (SBECD) at its research facility in Xi'an, China. Driven by the growing demand for effective formulation solutions for poorly soluble drugs, the company's scientists optimized inclusion complex technology to enhance drug solubility and stability. The achievement highlights the important role of SBECD in modern drug delivery systems and supports the development of high-quality pharmaceutical products worldwide.
Cyclodextrin vs Hydroxypropyl Betadex: compare cost, solubility performance, safety, regulatory status and development timeline to choose the best excipient for pharmaceutical formulation optimization and drug delivery systems.
Vonoprazan Fumarate has emerged as a next-generation solution for managing acid-related gastrointestinal disorders. Unlike conventional therapies, it delivers rapid, consistent, and long-lasting acid suppression, addressing common patient concerns such as delayed symptom relief, incomplete healing, and nighttime acid breakthrough. This article provides a comprehensive exploration of its mechanism, benefits, applications, and practical considerations for buyers and healthcare stakeholders.
Hydroxypropyl Betadex (HPBCD) is a widely used pharmaceutical excipient known for improving the solubility, stability, and bioavailability of poorly water-soluble drugs. By forming inclusion complexes, it enhances drug performance across oral, injectable, and ophthalmic formulations. Its excellent compatibility and safety profile make it a key material in modern drug development. With reliable quality and stable supply, HPBCD supports pharmaceutical companies in optimizing formulations and accelerating product development for global markets.
